We are live on ! Find out more
BSTG

Biostage, Inc. Common Stock
BSTG

Delisted

BSTG was delisted on the 5th of October, 2017.

32 hedge funds and large institutions have $3.86M invested in Biostage, Inc. Common Stock in 2015 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 10 increasing their positions, 9 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

11% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 9

14% less funds holding

Funds holding: 3732 (-5)

63% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 8

64% less capital invested

Capital invested by funds: $10.6M → $3.86M (-$6.72M)

Holders
32
Holders Change
-5
Holders Change %
-13.51%
% of All Funds
0.86%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
10
Reduced
9
Closed
8
Calls
Puts
Net Calls
Net Calls Change

BSTG Hedge Fund Activity: Q2 2015 in Review

32 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Biostage, Inc. Common Stock (BSTG) for Q2 2015, worth a combined $3.86M — down 64% from $10.6M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of BSTG and 3 opened new positions — a net loss of 5 holders — while 9 trimmed existing stakes and 10 added.

The largest buyer was Renaissance Technologies, adding an estimated $226K. The largest seller was 683 Capital Management, exiting entirely with an estimated $652K sold.

  • 32 institutional investors held Biostage, Inc. Common Stock (BSTG) as of Q2 2015, down from 37 in Q1 2015.
  • Funds reported $3.86M of Biostage, Inc. Common Stock stock for Q2 2015, down 64% quarter-over-quarter.
  • 3 funds opened new Biostage, Inc. Common Stock positions in Q2 2015 and 8 closed out, a net change of -5 holders.
  • The largest Biostage, Inc. Common Stock buyer in Q2 2015 was Renaissance Technologies, an estimated $226K added.
  • The largest Biostage, Inc. Common Stock seller in Q2 2015 was 683 Capital Management, an estimated $652K sold.

Based on aggregated 13F filings for Q2 2015.